Researchers Identify Microbial Fatty Acid That Mimics Statin Effects

A specific gut microbe produces a molecule that can cut arterial plaque buildup by approximately 50%, according to a study published Oct. 7, 2026, in the journal Nature. Researchers found that the bacterium, identified as Bacteroides uniformis, secretes a fatty acid that mimics the mechanism of widely prescribed cholesterol-lowering medications.

The discovery, led by a team from Sun Yat-sen University in Shenzhen, China, highlights a “natural statin” effect originating within the human digestive system. While many saturated fats are associated with increased cardiovascular risk, this specific molecule—pentadecanoic acid (C15:0)—is an odd-chain fatty acid that appears to actively protect the heart by regulating liver function.

Researchers identified a specific metabolic pathway where gut-derived molecules regulate cholesterol production in the liver.

The Statin-Like Mechanism

The study found that pentadecanoic acid targets HMG-CoA reductase, the same liver enzyme that traditional statin drugs are designed to inhibit. By suppressing this enzyme, the microbially produced fatty acid reduces the liver’s production of cholesterol and prevents it from accumulating in the arteries.

In laboratory tests involving mice prone to atherosclerosis, oral supplementation of C15:0 significantly slowed the progression of the disease. The fatty acid effectively halved the volume of fatty plaques within the arteries, suggesting that the gut-liver axis plays a more direct role in managing cholesterol than previously understood. This metabolic pathway offers a potential explanation for why some individuals maintain healthy cholesterol levels despite dietary factors.

Distinguishing “Good” Saturated Fats

Pentadecanoic acid is classified as an odd-chain saturated fatty acid, a category that differs structurally from the even-chain saturated fats found in processed meats and certain oils. While even-chain fats are often linked to inflammation and heart disease, research increasingly suggests that odd-chain variants like C15:0 may be essential for cellular health and metabolic stability.

Beyond the animal models, the researchers analyzed human stool samples to determine if these findings translated to clinical observations. They discovered that levels of both B. uniformis and pentadecanoic acid were significantly lower in patients diagnosed with coronary heart disease or dyslipidaemia (imbalanced blood fats) compared to healthy individuals. This correlation suggests that a deficiency in this specific gut microbe may be a contributing factor to cardiovascular vulnerability.

Future Clinical Potential

The identification of Bacteroides uniformis as a producer of C15:0 provides a new target for probiotic or postbiotic therapies. Rather than relying solely on synthetic drugs to manage cholesterol, future treatments might involve restoring the gut’s natural ability to produce these protective fatty acids.

While the reduction in plaque was observed in mice, the researchers noted that the presence of the microbe in healthy human populations indicates a shared biological mechanism. Further clinical trials will be necessary to determine the safety and efficacy of C15:0 supplements or B. uniformis probiotics in humans, but the study establishes a clear molecular link between microbial health and the prevention of arterial disease.

The post Researchers Identify Microbial Fatty Acid That Mimics Statin Effects appeared first on World Weekly News.